FIGURE 3.

Genome‐wide screening candidate drug‐resistant gene set and GO enrichment analysis. (A) Schematic overview of genome‐wide CRISPR/cas9 screening. (B) Counts of genes were positively selected during whole‐genome drug screening in HeLa or SiHa cells. (C) High confident cervical cancer drug‐resistant gene set includes 1074 genes, which were supported by both clinical and whole‐genome drug screening evidences. (D) Counts of genes were positively selected during whole‐genome drug screening in HeLa or SiHa cells for 1074 drug‐resistant genes. (E) The cluster of 17 drug‐resistant genes with significantly higher mutation frequencies in the drug‐resistant patients’ group. The left matrix: red patch indicates gene resistance to drugs. The middle bar: the colour indicates genes’ mutation frequencies. The right bar: the colour indicates genes’ significance of Fisher's test between drug‐sensitive and drug‐resistant patients’ groups. (F and G) Statistically significant biological processes enriched in 1074 drug‐resistant genes and the cell‐specific drug‐resistant gene. (H) PLXNB1, PLXNB2, and HERC2 were positively selected during whole‐genome cisplatin or paclitaxel screening in HeLa or SiHa cells